The Protective Effects Of Liraglutide On Ad Like Neurodegeneration

Glucagon-like peptide1(GLP-1) is a growth factor that has demonstrated neuro-protective properties in a range of studies. In an streprozotocin (STZ) intracerebro-ventricular injection mouse model of Alzheimer’s disease, we previously found protective effects on capacities of memory and learning, the reduction of amyloid synthesis and plaque load as well as the excessive phosphorylation of Tau and NFs in the brain. Here, we analyse the neuroprotective properties of the GLP-1analogue liraglutide on AD like neurodegeneration induced by oxidative stress in human neuroblastoma SH-SY5Y cells. We show that cell viability was enhanced by liraglutide treatment (MTT assay) in a dose-dependent way, while cytotoxicity (LDH assay) and apoptosis were reduced. In addition, the product of lipid peroxidation Malonyldialdehyde (MDA) were also reduced. Besides the apoptosis percentage evaluated by annexin-V/PI staining and Flow cytometry showed a downward trend. Moreover, we found the expression of the pro-survival Bcl-2protein also increased, while the expression of pro-apoptotic Bax protein reduced after the treatment of liraglutide. Furthermore, the excessive phosphorylated Tau and NFs was reduced by liraglutide treatment. In our study, we also illustrated that the PI3K-AKt signaling pathway may play a critical role in the protective effects of liraglutide on AD like neurodegeneration.